Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor
文献类型：期刊论文
| 作者 | Hu, Jianping1,2; Wang, Yingqing3 ; Li, Yanlian1; Xu, Lin2,3; Cao, Danyan1; Song, ShanShan3; Damaneh, Mohammadali Soleimani2,3; Wang, Xin1; Meng, Tao1; Chen, Yue-Lei1
|
| 刊名 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
 |
| 出版日期 | 2017-09-08 |
| 卷号 | 137页码:176-195 |
| 关键词 | BRD4 inhibitor Kinase BI-2536 Dihydroquinoxalin-2(1H)-one |
| ISSN号 | 0223-5234 |
| DOI | 10.1016/j.ejmech.2017.05.049 |
| 文献子类 | Article |
| 英文摘要 | Recent years have seen much effort to discover new chemotypes of BRD4 inhibitors. Interestingly, some kinase inhibitors have been demonstrated to be potent bromodomain inhibitors, especially the PLK1 inhibitor BI-2536 and the JAK2 inhibitor TG101209, which can bind to BRD4 with IC50 values of 0.025 mu M and 0.13 mu M, respectively. Although the concept of dual inhibition is intriguing, selective BRD4 inhibitors are preferred as they may diminish off-target effects and provide more flexibility in anticancer drug combination therapy. Inspired by BI-2536, we designed and prepared a series of dihydroquinoxalin2(1H)-one derivatives as selective bromodomain inhibitors. We found compound 54 had slightly higher activity than (+)-JQ1 in the fluorescence anisotropy assay and potent antiproliferative cellular activity in the MM.1S cell line. We have successfully solved the cocrystal structure of 52 in complex with BRD4-BD1, providing a solid structural basis for the binding mode of compounds of this series. Compound 54 exhibited high selectivity over most non-BET subfamily members and did not show bioactivity towards the PLK1 kinase at 10 or 1 mu M. From in vivo studies, compound 54 demonstrated a good PK profile, and the results from in vivo pharmacological studies clearly showed the efficacy of 54 in the mouse MM.1S xenograft model. (C) 2017 Elsevier Masson SAS. All rights reserved. |
| WOS关键词 | SMALL-MOLECULE INHIBITORS ; BROMODOMAIN LIGANDS ; DRUG DISCOVERY ; C-MYC ; BRD4 ; READER ; KINASE ; ACETYLATION ; BINDING ; TARGET |
| 资助项目 | National Natural Science Foundation of China[81330076] ; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" of China[2014ZX09507-002] ; "Personalized Medicines-Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020318] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000407412200015 |
| 出版者 | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/272486]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 药物化学研究室 |
| 通讯作者 | Shen, Jingkang; Miao, Zehong; Xiong, Bing |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Dept Med Chem, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China; 2.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Hu, Jianping,Wang, Yingqing,Li, Yanlian,et al. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2017,137:176-195. |
| APA | Hu, Jianping.,Wang, Yingqing.,Li, Yanlian.,Xu, Lin.,Cao, Danyan.,...&Xiong, Bing.(2017).Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,137,176-195. |
| MLA | Hu, Jianping,et al."Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 137(2017):176-195. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。